Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study.

BMC Infect Dis · 2016 · PMC5100179 · PMID 27821093

Europe PMC DOI

hedged sentence

0.3240

closest p · 6.5× alpha

0.3240

boldest claim

The sentences

showed a trendp = 0.324not close (p > 0.1)

Efficacy analysis The difference in time to resolution of all influenza-like symptoms between treatment groups was not statistically significant but showed a trend towards improvement in subjects in the inosine pranobex group compared with subjects in the placebo group (HR: 1.175; 95 % CI: 0.806, 1.714; p = 0.324) (Fig. 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.